GPS2

Across TCGA pan-cancer cohorts, GPS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPS2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GPS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GPS2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where GPS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.394	0.669	.004	14	view →
LSCC	OS	Quartile	All	1.000	0.722	.005	9	view →
HNSC	DFS	Quartile	All	1.000	0.870	.008	8	view →
GBM	OS	Quartile	All	0.596	0.331	.016	3	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GPS2–PDAC (OS)

Open the PDAC breakdown →